168098-94-0

Usage

Explanation

This is the chemical name of the compound, which is also known as Mefloquine.

Explanation

Mefloquine has properties that help prevent and treat malaria, a disease caused by Plasmodium parasites.

Explanation

Mefloquine's chemical structure consists of a 2-amino-4-alkylamino-6-piperazine core, which is similar to the structure of quinine, another antimalarial drug.

Explanation

Mefloquine works by disrupting the life cycle of the Plasmodium parasites, preventing them from multiplying and causing further harm to the host.

Explanation

Mefloquine is available in tablet form, making it easy to administer and take as a medication.

Explanation

Some individuals may experience side effects from taking Mefloquine, which can include gastrointestinal issues, dizziness, and psychiatric symptoms.

Explanation

Due to the potential for psychiatric side effects, Mefloquine is not advised for individuals with a history of mental health issues, as it may exacerbate their condition.

Category

Antimalarial chemical compound

Structural relation

2-amino-4-alkylamino-6-piperazine, related to quinine

Mechanism of action

Interferes with growth and reproduction of malaria parasites in red blood cells

Form

Tablet

Usage

Prophylactic drug for travelers to malaria-endemic areas

Side effects

Nausea, dizziness, psychiatric symptoms

Contraindication

Not recommended for people with a history of psychiatric disorders

Upstream product

• 456-47-3 3-fluoro-benzenemethanol 
• 10310-21-1 2-Amino-6-chloropurin 
• 34798-95-3 2-amino-N,N,N-trimethyl-9H-purine-6-ylammonium chloride 

Downstream Products

• 73-40-5 2-amino-6-hydroxypurine 

Relevant academic research and scientific papers

A convenient procedure for the synthesis of O6-benzylguanine derivatives by phase transfer catalysis

A convenient procedure by phase transfer catalysis has been developed for the synthesis of O6-BG (1) and its derivatives hydroxymethyl-BG (2a-c), halo-BG (3a-c, 4a-c, 5a-c, 6a-c), methoxy-BG (7), and methyl-BG (8). Compounds 2b, 2c, 4b, 4c, 5b, 5c, 6a, and 6c are new compounds.

Potentiation of the cytotoxicity of chloroethylnitrosourea by O6-arylmethylguanines

It was reported recently that monomeric O6-benzylguanine (1) acts as an alternative substrate for a DNA repair enzyme, O6-alkylguanine-DNA alkyltransferase (AGT), and that therefore pretreatment of cells with 1 induces depletion of AGT resulting in an enhanced cytotoxic response to alkylating antitumor agents. In order to study the interaction of O6-benzylguanine derivatives with AGT and to obtain greater AGT depletion, me synthesized the following O6-arylmethylguanine derivatives and related compounds: O6-(4-, 3- and 2-fluorobenzyl)guanines (2, 3, 4), O6-(4-,3- and 2-trifluoromethylbenzyl)guanines (5, 6, 7), O6-(4-, 3- and 2-pyridylmethyl)guanines (8, 9, 10), O6-(2- and 1-naphthylmethyl)guanines (11, 12), O6-biphenylmethylguanine (13), S and Se analogues of O6-benzylguanine (14, 15) and O6-phenylguanine (16). Ten of these are new compounds. All these compounds were tested for their potentiation of N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl] (ACNU) cytotoxicity using HeLa S3 and C6-1 cells. Compounds 2, 3, 5, 8, 9, 11 and 13 were active, as was 1. Compounds 7 and 12, with a substituent at the a position of the benzyl group, and compound 10, the a-nitrogen analogue of 1, were almost completely devoid of potentiating activity. These results suggest that the a-position of the O6-benzyl group plays an important role in the interaction of O6-benzylguanines with AGT. Of the other compounds, 4 and 6 exhibited very weak activity and 14, 15 and 16 were inactive. Possible reasons for these differences in activity are discussed in relation to the biomimetic dealkylation rates of O6-benzylguanine derivatives and the chemical characteristics of their substituents.